LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

新变异的小细胞肺癌被发现

By LabMedica International staff writers
Posted on 01 Aug 2018
Print article
图片:一根支气管,被染成红色和蓝色的细胞是支气管上皮的一部分。这表明其中有一种罕见细胞(染成蓝绿色),应该是一种丛状细胞。科学家发现了起源于这些细胞的一种新型肺癌,它过表达POU2F3这种调节基因的蛋白,有望成为治疗的靶体(图片蒙冷泉港实验室惠赐)。
图片:一根支气管,被染成红色和蓝色的细胞是支气管上皮的一部分。这表明其中有一种罕见细胞(染成蓝绿色),应该是一种丛状细胞。科学家发现了起源于这些细胞的一种新型肺癌,它过表达POU2F3这种调节基因的蛋白,有望成为治疗的靶体(图片蒙冷泉港实验室惠赐)。

小细胞肺癌(SCLC)被普遍视为肺神经内分泌细胞的肿瘤;然而,这种病的一种变体缺少神经内分泌特征,最近的一篇论文对此做了描述。

 

SCLC是一种极度需要新药的癌症,它没有专门的疗法,经常很早就扩散。化疗、放疗和手术只能使6%的患者从确诊起存活五年,所有的肺癌病例中约10%15%SCLC

 

美国纽约冷泉港实验室(www.cshl.edu)的科研人员与其他科学家合作,用专门领域的CRISPR筛查人类癌细胞系,认定转录因子(TF) POU 2类同源框蛋白3POU2F3,又称SKN-1a/OCT-11)极度依赖一部分SCLC细胞系。分析人类SCLC样本发现,POU2F3只在变异的SCLC肿瘤里表达,这样的肿瘤不表达神经内分泌标志物,却表达化学感应细胞系的标志物,称作丛状细胞。

 

科研小组利用了染色质特征测定和RNA特征测定的检查,并提供证据证明POU2F3SCLC变体的丛状细胞身份的主要调节者。另外,他们显示,大多数SCLC肿瘤可归为三种品系之一:表达POU2F3、无刚毛鳞甲同源物1(ASCL1)或神经元分化1(NEUROD1)。结果显示,POU2F3是细胞身份的决定因素,并且依赖SCLC的丛状细胞样变体,它可能反映以前未识别的起源细胞或者SCLC的转分化事件。

 

该研究的论文发表于2018626日的《基因与发育》(Genes & Development)杂志。第一作者、博士后研究人员Yu-Han Huang博士说:过去,我们把不同形式的SCLC混在一起,因为在显微镜玻片上它们看起来相似,但是现在我们的一些分子检验能轻松鉴别这些恶性病变。我们的成功表明,我们应该为它们设计单独的检查,找到针对不同类型肿瘤的疗法。

Related Links:

冷泉港实验室>>> www.cshl.edu


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more